LIXTW LIXTE BIOTECHNOLOGY HOLDINGS INC. WT EX
- 0.0510
- -0.0037-6.76%
LIXTE BIOTECHNOLOGY HOLDINGS INC. WT EX News
10-Q: Quarterly report
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on "Therapeutic Over-Activation in Cancer"
Recent Findings Relate to LIXTE's Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard's Dana Farber Cancer Institute in Boston PASADENA, CA, May 08, 2024 (GLOBE NE
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE
LIXTE Provides Update on Progress With LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company")
Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research
Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, I
LIXTE Biotechnology Enters Into Exclusive Immune Oncology Patent License Agreement With NINDS and NCI
Agreement Focuses on Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the
First Patient Dosed With LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to
LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
Extension Agreement Follows Successful Two-Year Collaboration in Colon Cancer PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) announced that it has
LIXTE Biotechnology Holdings Announces the Passing of Its Founder, John S. Kovach
PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A
LIXTE Appoints Bas Van Der Baan as President and Chief Executive Officer
Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE"
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA,
LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced the closing of its previously announced registered direct offering of 583,334
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company") today announced it has entered into a securities purchase agree
Preclinical Results of LIXTE Biotechnology's Collaboration With Netherlands Cancer Institute Reveal Novel Mechanism by Which LIXTE's Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
Results Provide Striking Molecular Evidence that Inhibiting PP2A with LB-100 Sensitizes Cancer Cells to Immunotherapy and Chemotherapy PASADENA, CA, July 17, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings,
Lixte Biotechnology (NASDAQ:LIXTW) Shares Down 14.7%
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTW – Get Rating) dropped 14.7% on Wednesday . The stock traded as low as $0.11 and last traded at $0.11. Approximately 273 shares traded hands during trad
Lixte Biotechnology (NASDAQ:LIXTW) Shares Down 10.3%
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTW – Get Rating) dropped 10.3% on Thursday . The company traded as low as $0.13 and last traded at $0.13. Approximately 7,678 shares changed hands during
Lixte Biotechnology (NASDAQ:LIXTW) Trading Down 10.3%
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTW – Get Rating)'s share price fell 10.3% on Thursday . The stock traded as low as $0.13 and last traded at $0.13. 7,678 shares were traded during mid-da
Lixte Biotechnology (NASDAQ:LIXTW) Stock Price Up 68.7%
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTW – Get Rating) rose 68.7% during trading on Wednesday . The company traded as high as $0.18 and last traded at $0.11. Approximately 36,002 shares chang
Americans are borrowing money again, and consumer credit is at a record high.
The original title: Americans began to "borrow money" again, and consumer credit reached record highs. Americans began to "borrow money" again, and reached a level unprecedented in more than a decade. U.S. consumer demand for car loans and leases, general credit cards and personal loans rose 39% in April from a year earlier, according to data from credit reporting firm Aikefei. The index is also up 11 per cent compared with April 2019. Aikefei said the number of new car loans and leases hit an all-time high in March. The number of general-purpose credit cards issued in March also hit an all-time high. Aikefei's data can be traced back to 2010. This has something to do with
Analysis
Price Target
No Data
